CHELMSFORD, MA, USA & NOVI, MI, USA & DÜSSELDORF, Germany & TOKYO, Japan I July 02, 2025 I Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan (generic ...

Two oral presentations to highlight the safety, immunogenicity, and future development of AV-1959R for primary and secondary prevention of Alzheimer’s disease IRVINE, CA, USA I July 1, 2025 I Nuravax ...

MADRID, Spain I July 2, 2025 I mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the ...

Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties ...

ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR ...

MONTPELLIER, France I July 01, 2025 I Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of ...

OSLO, Norway I June 30, 2025 I BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they ...

SAN DIEGO, CA, USA I June 30, 2025 I Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

LUND, Sweden I July 1, 2025 I Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous ...

CAMBRIDGE, MA, USA I June 30, 2025 I XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance ...

TAIPEI, Taiwan and SHANGHAI, China and SAN FRANCISCO, CA, USA I July 1, 2025 I HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company ...

LAUSANNE, Switzerland and COPENHAGEN, Denmark I July 01, 2025 I ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine ...